Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 61
- Registration Number
- NCT03164772
- Locations
- 🇺🇸
Research Facility, Milwaukee, Wisconsin, United States
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 67
- Registration Number
- NCT02963831
- Locations
- 🇺🇸
Research Facility, Charlottesville, Virginia, United States
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 2
- Registration Number
- NCT02898116
- Locations
- 🇺🇸
Research Facility, New York, New York, United States
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 73
- Registration Number
- NCT02735239
- Locations
- 🇬🇧
Research Facility, Southampton, United Kingdom
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 6
- Registration Number
- NCT02716805
- Locations
- 🇺🇸
Research Facility, New York, New York, United States
Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 20
- Registration Number
- NCT02659540
- Locations
- 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 58
- Registration Number
- NCT02643303
- Locations
- 🇺🇸
Research Facility, Charlottesville, Virginia, United States
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 53
- Registration Number
- NCT02431559
- Locations
- 🇺🇸
Research Facitlity, Phoenix, Arizona, United States
🇨🇭Research Facility, Lausanne, Switzerland
Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 159
- Registration Number
- NCT02336165
- Locations
- 🇦🇺
Research Facility, Melbourne, Australia
Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 9
- Registration Number
- NCT02252211
- Locations
- 🇦🇺
Austin Health, Heidelberg, Victoria, Australia
© Copyright 2024. All Rights Reserved by MedPath